College of Pharmacy, Touro University, California, USA.
Arch Med Res. 2021 Jan;52(1):15-24. doi: 10.1016/j.arcmed.2020.09.010. Epub 2020 Sep 10.
The Coronavirus disease 2019 (COVID-19) pandemic has spread to almost all nooks and corners of the world. There are numerous potential approaches to pharmacologically fight COVID-19: small-molecule drugs, interferon therapies, vaccines, oligonucleotides, peptides, and monoclonal antibodies. Medications are being developed to target the spike, membrane, nucleocapsid or envelope proteins. The spike protein is also a critical target for vaccine development. Immunoinformatic approaches are being used for the identification of B cell and cytotoxic T lymphocyte (CTL) epitopes in the SARS-CoV-2 spike protein. Different vaccine vectors are also being developed. Chemical and physical methods such as formaldehyde, UV light or β-propiolactone are being deployed for the preparation of inactivated virus vaccine. Currently, there are many vaccines undergoing clinical trials. Even though mRNA and DNA vaccines are being designed and moved into clinical trials, these types of vaccines are yet to be approved by regulatory bodies for human use. This review focuses on the drugs and vaccines being developed against the COVID-19.
新型冠状病毒肺炎(COVID-19)疫情已蔓延至世界各个角落。有许多潜在的方法可以在药理学上对抗 COVID-19:小分子药物、干扰素疗法、疫苗、寡核苷酸、肽和单克隆抗体。正在开发针对刺突、膜、核衣壳或包膜蛋白的药物。刺突蛋白也是疫苗开发的关键靶点。免疫信息学方法正被用于鉴定 SARS-CoV-2 刺突蛋白中的 B 细胞和细胞毒性 T 淋巴细胞(CTL)表位。不同的疫苗载体也正在开发中。化学和物理方法,如甲醛、紫外线或β-丙内酯,正被用于制备灭活病毒疫苗。目前,有许多疫苗正在进行临床试验。尽管 mRNA 和 DNA 疫苗正在设计并进入临床试验,但这些类型的疫苗尚未获得监管机构批准用于人体。本文重点介绍针对 COVID-19 开发的药物和疫苗。